Saturday, February 01, 2014 6:29:44 PM
HRTX @ Stockcharts
Heron Therapeutics Provides Update on Sustol Resubmission
http://finance.yahoo.com/news/heron-therapeutics-provides-sustol-resubmission-130000550.html
Heron Therapeutics (formerly A.P. Pharma, Inc.) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product, Sustol (formerly known as APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.
The Company's lead product, Sustol™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its Sustol New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration late in the first quarter of 2014.
http://www.herontx.com/aboutus-main.html
Heron Therapeutics Provides Update on Sustol Resubmission
http://finance.yahoo.com/news/heron-therapeutics-provides-sustol-resubmission-130000550.html
Heron Therapeutics (formerly A.P. Pharma, Inc.) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product, Sustol (formerly known as APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.
The Company's lead product, Sustol™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its Sustol New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration late in the first quarter of 2014.
http://www.herontx.com/aboutus-main.html
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
